What is cancer supportive care?
How the AURA3 trial has changed conversations about re-biopsy in second-line lung cancer treatment
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr